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Background: Evidence remains scarce regarding the property of serum bilirubin levels as a prognostic factor for
the incidence of mortality in dialysis patients. Here, we aimed to examine the association between serum bilirubin
levels and mortality in patients with diabetes initiating hemodialysis.
Methods: This was a single-center, observational, historical cohort study of 395 Japanese patients with diabetes
initiating chronic hemodialysis. There were 98 women and 297 men, and the mean (±SD) age was 61 ± 12 years.
Patients were dichotomized at the baseline median level of serum bilirubin (0.3 mg/dL). The endpoints were the
incidence of all-cause and cause-specific mortality. Hazard ratios for these endpoints were estimated using the
Fine-Gray subdistribution hazard model and cause-specific hazard model because of the presence of competing
risks.
Results: During a median follow-up period of 3.9 years (range; 0.0–10.7 years), there were 83 cases of death,
consisting of 39 and 44 cases from atherosclerotic cardiovascular diseases (ASCVDs) and non-ASCVDs, respectively.
In the multivariate competing risks analysis, patients with lower bilirubin levels were associated with higher risk of
ASCVD-related mortality (subdistribution hazard ratio 3.57, p = 0.015) but not with non-ASCVD-related mortality
(0.83, p = 0.665) than those with higher bilirubin levels. Analysis treating bilirubin levels as a continuous variable,
as well as cause-specific models yielded the similar results.
Conclusions: Lower serum levels of bilirubin may be predictive of higher risk of ASCVD-related mortality in
patients with diabetes initiating chronic hemodialysis. There was no relationship between levels of bilirubin
and non-ASCVD-related mortality.
Keywords: Bilirubin, Diabetes mellitus, Hemodialysis, Mortality, Competing risks analysisBackground
Patients with diabetes undergoing dialysis still experi-
ence extremely high mortality [1, 2], the leading causes
of which have been shown to be atherosclerotic cardio-
vascular diseases (ASCVDs) [3]. Several lines of evidence
have suggested that increased oxidative stress is highly
prevalent in patients receiving dialysis, contributing to
the increased incidence of the adverse outcomes [4].
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effects of antioxidant therapy on the development of
ASCVDs [5, 6], despite a number of unsuccessful clinical
trials using a range of interventions aimed to improve
the prognosis in this population [4, 7].
Bilirubin possesses a potent antioxidant activity, effect-
ively scavenging peroxyl radicals and suppressing oxida-
tion of lipids and lipoproteins [8]. Clinical studies have
shown that higher levels of serum bilirubin, even within
normal range, are associated with reduced all-cause
mortality as well as the incidence of ASCVD in patients
without chronic kidney disease (CKD) [9, 10]. We andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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bin possess protective effects on the incidence of micro-
and macrovascular complications in diabetic patients
[11–14]. In a cross-sectional study of Japanese dialysis
patients with type 2 diabetes, lower serum bilirubin
levels were significantly associated with higher presence
of ASCVDs [15]; however, evidence remains scarce
regarding property of serum bilirubin levels as a prog-
nostic factor for the incidence of all-cause and ASCVD-
related mortality in dialysis patients with diabetes. Here,
we aimed to examine the hypothesis that serum bilirubin
levels are a predictor for mortality in diabetic patients
initiating maintenance hemodialysis.
Methods
Study design
This was a single-center, longitudinal, observational
study using a historical cohort of adult Japanese patients
with diabetes initiating chronic hemodialysis. This study
was designed in adherence to the Declaration of Helsinki
and approved by the Ethics Committee of Tokyo
Women’s Medical University Hospital. Since this was an
observational but not prospective intervention study, the
Ethics Committee provided a waiver of informed con-
sent. The present study used data from a clinical infor-
mation system (electronic medical records).
Participants
From the hospital database, we initially collected data
on 549 consecutive patients with type 1 and type 2 dia-
betes and specific types of diabetes due to other causes
who newly initiated chronic hemodialysis at the Dialysis
Unit, Department of Medicine, Diabetes Center, Tokyo
Women’s Medical University School of Medicine, Tokyo,
Japan, during the period between January 2003 and March
2013. Types of diabetes were diagnosed according to the
Japan Diabetes Society criteria [16]. In this study, we
excluded patients if they had cholelithiasis (n = 7), liver
cirrhosis (n = 7), chronic hepatitis B or C (n = 41), or
malignant disease (n = 9) at baseline, as well as those with
missing values for baseline profiles (n = 90). Overall, a total
of 395 patients were included in the analysis.
Measurements
At the beginning of initial hemodialysis therapy, subjects
underwent baseline anthropometric and physical exami-
nations. Serum bilirubin levels were measured by an en-
zymatic method involving bilirubin oxidase using an
automatic analyzer (Hitachi Labospect 008; Hitachi,
Japan; normal range 0.2–1.2 mg/dL). The lower meas-
urement limitation of bilirubin was 0.1 mg/dL; therefore,
the levels less than 0.1 mg/dL in 12 patients were treated
as 0.1 mg/dL. High-density lipoprotein (HDL) choles-
terol levels were determined using polyethylene glycol-pretreated enzymes, triglycerides using enzymatic
methods, and low-density lipoprotein (LDL) cholesterol
using enzymatic methods or Friedewald’s equation (if
levels of triglycerides <400 mg/dL). Serum creatinine
concentrations were determined using an enzymatic
method. HbA1c was measured utilizing a set of calibra-
tors assigned by the Japan Diabetes Society (JDS) (nor-
mal range, 4.3–5.8 %); therefore, in the present study,
National Glycohemoglobin Standardization Program
(NGSP)-equivalent values were obtained using the fol-
lowing equation: HbA1c (%) = 1.02 × HbA1c (JDS) (%) +
0.25 % [17]. GFR was estimated using the following
equation, as proposed by the Japanese Society for Neph-
rology: estimated GFR (eGFR: mL/min/1.73 m2) = 194 ×
age (years)−0.287 × serum creatinine level (mg/dL)−1.094 ×
(0.739 if female) [18].
Follow-up and endpoints
After receiving initial several times of hemodialysis ses-
sions at the dialysis unit of the hospital, all the patients
were referred to and underwent chronic dialysis in out-
patient hemodialysis clinics. Most of patients were also
seen at the hospital thereafter for the purpose of gly-
cemic control only.
The endpoints were the incidence of all-cause mortal-
ity and cause-specific mortality, the latter of which was
classified into ASCVD-related and non-ASCVD-related
mortality. The causes of ASCVD-related death were de-
fined as follows: acute myocardial infarction, other ische-
mic heart disease including angina pectoris, heart
failure, stroke such as cerebral hemorrhage and cerebral
infarction, unhealed diabetic foot disease caused by per-
ipheral arterial disease, and sudden death. Vital status of
patients and cause of death in diseased patients were
confirmed by direct reference to the hospital medical
chart or inquiring to dialysis clinic. Patients were
censored when they were lost to follow-up or at the ad-
ministrative censoring date (April 30, 2014). Loss to
follow-up was defined as the last visit 6 months or more
before the administrative censoring date.
Statistical analysis
Data were expressed as percentage, arithmetic mean
(standard deviation: SD), or median (range), as appropri-
ate according to the data distribution. Student’s t test or
Mann-Whitney U test and Fisher’s exact probability test
were used to compare continuous and categorical data
between two groups, respectively.
In consideration of the presence of competing risks,
for example, death from causes other than ASCVDs in
the analysis examining time to ASCVD-related death,
cumulative incidence function (CIF) of mortality [19, 20]
and the Fine and Gray subdistribution hazard model, as
well as cause-specific hazard model [20, 21], were used
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and Cox proportional hazard model, respectively, as
these latter methods may overestimate the risk of events
by undermining the competing risks. In this study, kid-
ney transplantation was also treated as a competing risk.
In the multivariate models, the following covariates were
incorporated: age, sex, duration of diabetes mellitus, his-
tory of ASCVDs, smoking status (current/ever versus
never), date of hemodialysis initiation (January 2003 to
December 2008 versus January 2009 to March 2013),
body mass index, systolic blood pressure, diastolic blood
pressure, HbA1c, logarithmically transformed triglycer-
ides, HDL cholesterol, and LDL cholesterol.
P values <0.05 were considered statistically significant.
All statistical analyses were performed using SAS version
9.4 (SAS Institute, Cary, NC).Table 1 Baseline demographic and laboratory data in patients dicho
Below the median
Age (years) 59 ± 13
Men (%) 73.8
Type 2 diabetes (%) 91.1
Duration of diabetes (years) 18 ± 9
Diabetic retinopathy (%) 92.7
Medication for diabetes (none/oral/insulin) 25.1/6.3/68.6
BMI (kg/m2) 24.7 ± 4.2
Systolic blood pressure (mmHg) 157 ± 24
Diastolic blood pressure (mmHg) 78 ± 13
Smoking (current or ever, %) 62.3
ASCVD (%) 57.1
Date of hemodialysis initiation
January 2003–December 2008 77.5
January 2009–March 2013 22.5
Laboratory data
Hemoglobin (g/dL) 8.8 ± 1.2
HbA1c (NGSP) (%) 6.2 ± 1.1
Triglycerides (mg/dL) 125 (38–1358)
HDL cholesterol (mg/dL) 42 ± 15
LDL cholesterol (mg/dL) 106 ± 39
Albumin (g/dL) 3.0 ± 0.5
Creatinine (mg/dL) 8.58 ± 2.25
eGFR (mL/min/1.73 m2) 5.7 ± 1.5
Total bilirubin (mg/dL) 0.2 (0.1–0.2)
AST (U/L) 17 ± 10
ALT (U/L) 13 ± 12
γ-GT (U/L) 18 (5–235)
Data are expressed as percentage, mean ± SD, or median (range)
BMI body mass index, ASCVD atherosclerotic cardiovascular disease, eGFR estimated
transaminase, γ-GT γ-glutamyl transferaseResults
Baseline characteristics
Of 395 patients studied, there were 98 women and 297
men, and the mean (±SD) age was 61 ± 12 years (range
28–98 years). The vast majority (93.7 %) had type 2 dia-
betes. Median known duration of diabetes was 18 years
(range 1–60 years). Median serum bilirubin level was
0.3 mg/dL (range 0.1–0.8 mg/dL), at which the subjects
were dichotomized. Clinical characteristics and labora-
tory data in patients with higher and lower levels of
serum bilirubin are presented in Table 1. Those with
lower bilirubin levels were likely to be younger, exhibit-
ing higher frequencies of retinopathy and ASCVD,
higher systolic blood pressure and LDL cholesterol
levels, and lower hemoglobin levels than those with
higher bilirubin levels.tomized at the median of serum bilirubin levels
(n = 191) Above the median (n = 204) p value
62 ± 12 0.012
76.5 0.562
96.1 0.061
19 ± 10 0.617
77.5 <0.001
25.5/17.2/57.3 0.002
24.9 ± 4.8 0.648
151 ± 19 0.007
77 ± 13 0.764
58.8 0.537
44.1 0.012
33.3 <0.001
66.7
9.3 ± 1.2 <0.001
6.3 ± 1.0 0.522
114 (29–887) 0.163
44 ± 14 0.202
96 ± 36 0.009
3.2 ± 0.4 <0.001
8.26 ± 1.89 0.123
6.0 ± 2.5 0.130
0.4 (0.3–0.8) <0.001
17 ± 8 0.977
12 ± 9 0.593
17 (7–416) 0.828
glomerular filtration rate, AST aspartate transaminase, ALT alanine
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During a median follow-up period of 3.9 years (range
0.0–10.7 years), there were 83 deceased cases, in which
39 and 44 resulted from ASCVD and non-ASCVD, re-
spectively. The causes of 44 non-ASCVD-related deaths
were as follows: cancer (n = 8), infection (n = 14), dis-
seminated intravascular coagulation (n = 1), refusal of
receiving hemodialysis (n = 1), and unknown etiology
(n = 20). Twenty patients underwent kidney transplant-
ation, and 42 patients were lost to follow-up.
CIF of all-cause mortality tended to be higher in pa-
tients with lower bilirubin levels than those with
higher bilirubin levels (Gray’s test: p = 0.054, Fig. 1a).
Cumulative incidence of ASCVD-related mortality was
significantly higher in those with lower bilirubin levels
(p = 0.005, Fig. 1b). No significant difference was
observed in the CIF of non-ASCVD-related mortality
(p = 0.807, Fig. 1c).
As shown in Table 2, multivariate subdistribution haz-
ard ratio for patients with lower versus higher bilirubin
levels was 3.57 (p = 0.015) for ASCVD-related mortality
with statistical significance and 1.56 (p = 0.162) for all-
cause mortality with marginal significance. Hazard ratio
for non-ASCVD-related mortality was not statistically
significant. Similar results were obtained in the analysis
treating bilirubin levels as a continuous variable, indicat-
ing that every 0.1-mg decrease in serum bilirubin level
was associated with 2.3 times (p = 0.011) and 1.3 times
(p = 0.121) higher risk of ASCVD-related mortality and
all-cause mortality, respectively (Table 3). Results of
cause-specific hazard models were almost identical to
those of subdistribution models (Tables 2 and 3).Fig. 1 a Cumulative incidence of the all-cause mortality between the lower a
function (p = 0.054, Gray’s test). b Cumulative incidence of the atherosclerotic
higher bilirubin groups estimated using the cumulative incidence function (p
mortality between the lower and higher bilirubin groups estimated using theDiscussion
In this single-center, observational, historical cohort
study of Japanese patients with diabetes starting chronic
hemodialysis, we found a significant association of lower
versus higher serum bilirubin levels with 2.3 times
higher risk of ASCVD-related mortality. Lower serum
levels of bilirubin were also associated with higher risk
of all-cause mortality; however, the hazard ratio was not
statistically significant. These negative relationships were
confirmed by treating bilirubin levels as a continuous
variable. Furthermore, these relationships were inde-
pendent of other variables that are well-known risk fac-
tors for the development of ASCVDs. In contrast, there
was no relationship between levels of bilirubin and non-
ASCVD-related mortality.
A previous cohort study from Taiwan first identified
lower bilirubin levels as a risk factor for incident
ASCVD-related and all-cause mortality in dialysis pa-
tients with non-specific underlying kidney diseases
[22]. Our study restricting to patients with diabetes
yielded the consistent results; however, the previous
study used conventional Kaplan-Meier survival analysis
and Cox proportional hazard model for estimating the
event-free survival and hazard ratio, despite the pres-
ence of competing risks including kidney transplant-
ation and losses to follow-up. These classical survival
analyses have been shown to be inappropriate in the
presence of competing risks, yielding the potential for
biases [22]. To overcome these limitations, we used
competing risks analysis and confirmed that the inverse
association of serum bilirubin and ASCVD-related
mortality was robust.nd higher bilirubin groups estimated using the cumulative incidence
cardiovascular disease (ASCVD)-related mortality between the lower and
= 0.005, Gray’s test). c Cumulative incidence of the non-ASCVD-related
cumulative incidence function (p = 0.807, Gray’s test)
Table 2 Hazard ratio for patients with lower versus higher
bilirubin levels
Cause of
death
Subdistribution model Cause-specific model
HR (95 % CI) p value HR (95 % CI) p value
All causes 1.56 (0.83–2.94) 0.162 1.45 (0.83–2.50) 0.192
ASCVD 3.57 (1.28–10.00) 0.015 3.23 (1.30–8.33) 0.013
Non-ASCVD 0.83 (0.37–1.89) 0.665 0.83 (0.40–1.72) 0.609
Patients were dichotomized at the median (0.3 mg/dL) of bilirubin levels.
Hazard ratios for mortality in patients with lower versus higher bilirubin levels
were estimated using the Fine-Gray subdistribution hazard model and cause-
specific hazard model. The following variables were incorporated as independent
variables: age, sex, duration of diabetes mellitus, history of ASCVD, smoking, date
of hemodialysis initiation, body mass index, systolic blood pressure, diastolic
blood pressure, HbA1c, hemoglobin, serum albumin, logarithmically transformed
triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein
cholesterol
HR hazard ratio, CI confidence interval, ASCVD atherosclerotic
cardiovascular disease
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ies showing beneficial effects of bilirubin on ASCVDs in
patients with several conditions [9, 11, 12, 15]; however,
these observational studies including ours are unable to
infer the causal relationship between levels of bilirubin
and the outcomes. In this study, patients with lower
levels of bilirubin were likely to manifest higher systolic
blood pressure and LDL cholesterol levels at baseline;
however, the effects of bilirubin were independent of
these potential risk factors for ASCVDs. The most
likely explanation may be that bilirubin possesses as a
potent antioxidant, effectively scavenging peroxyl radi-
cals and suppressing oxidation of lipids and lipopro-
teins [8]. In a large population-based cohort study from
the UK, patients with Gilbert syndrome, a common dis-
order of unconjugated hyperbilirubinemia caused by a
mutation in the gene promoter for bilirubin uridine
glucuronyl transferase 1A1 (UGT1A1) [23], tended to
have a much lower mortality rate than patients without
evidence of the condition [24]. Total bilirubin levels
and the bilirubin-associated UGT1A SNPs tended to be
associated with all-cause mortality in patients with typeTable 3 Hazard ratio for of 0.1 mg/dL decrease in serum
bilirubin levels
Cause of
death
Subdistribution model Cause-specific model
HR (95 % CI) P value HR (95 % CI) P value
All causes 1.28 (0.93–1.75) 0.121 1.25 (0.95–1.61) 0.107
ASCVD 2.27 (1.20–4.35) 0.011 2.17 (1.35–3.57) 0.002
Non-ASCVD 0.88 (0.62–1.27) 0.507 0.88 (0.63–1.23) 0.451
Hazard ratios for 0.1 mg/dL decrease in serum bilirubin levels for mortality was
estimated using the Fine-Gray subdistribution hazard model and cause-specific
model. The following variables were incorporated as independent variables: age,
sex, duration of diabetes mellitus, history of ASCVD, smoking, date of hemodialysis
initiation, body mass index, systolic blood pressure, diastolic blood pressure,
HbA1c, hemoglobin, serum albumin, logarithmically transformed triglycerides,
high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol
HR hazard ratio, CI confidence interval, ASCVD atherosclerotic cardiovascular
disease2 diabetes without kidney disease [25]. Furthermore,
the above Taiwanese cohort study of hemodialysis pa-
tients showed that UGT1A1 gene polymorphism had
strong effects on serum bilirubin levels and also influ-
enced the incidence of ASCVD and all-cause mortality
[22]. These clinical studies strongly implicate lower
levels of bilirubin in the pathogenesis of ACSCVDs
through increased oxidant properties.
In this study, the association between bilirubinemia
and non-ASCVD mortality, mainly from cancer and in-
fection, was not observed. Cohort studies examining
the association of bilirubin with incidence of and mor-
tality from cancer have resulted in conflicting findings
[26–28]. In our study, there were only eight cases with
cancer-related mortality, limiting meaningful analysis
to determine the cause-specific associations. Regarding
infectious disease, bilirubin has also been known to
have anti-inflammatory effects. The defensive role of
bilirubin on infection was first shown almost 8 decades
ago [29]; however; whether hypobilirubinemia is associ-
ated with higher incidence of infectious diseases, espe-
cially in patients with diabetes and end-stage renal
disease (ESRD), is largely unknown. Future investiga-
tions including a large sample size are needed to deter-
mine the association in this population.
In agreement with a previous study [15], serum levels
of bilirubin in the patients with ESRD were lower, rais-
ing possibilities that some uremic substrates interfere
in the measurement and alter metabolism of serum
bilirubin. To the best of our knowledge, we were unable
to find these possibilities. Alternatively, another possi-
bility is that hypobilirubinemia may be one of the
causative factors in the development of ESRD in
diabetic patients [11–14].
The present study has several limitations. First, we exam-
ined an ethnically homogenous population at a single urban
university hospital in Japan; therefore, generalization of the
present findings may be limited. Second, we were unable to
completely exclude patients with hepatobiliary or hemolytic
disease. Third, we did not evaluate time-dependent changes
in serum bilirubin levels, lipid parameters, HbA1c, blood
pressure, BMI, or change in medications during follow-up.
Fourth, we did not differentiate direct and indirect bilirubin
from total serum bilirubin. We also did not evaluate any
genetic factors which regulate bilirubin concentration. Fifth,
90 patients with missing values at baseline were excluded,
42 patients were lost to follow-up, and the causes of 20
cases among 44 non-ASCVD-related deaths were unknown
etiology, which may add some bias in the analyses. Finally,
this study was carried out using a relatively small cohort.
Conclusions
The present single-center observational cohort study
may provide evidence for the clinical usefulness of
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tice, as the predictor for ASCVD-related mortality in pa-
tients with diabetes initiating hemodialysis. Meanwhile,
bilirubin levels were not associated with the incidence of
non-ASCVD-related mortality. The present findings
should be confirmed in further studies including a larger
sample size and a multicenter design. We believe that
the present findings lead to the possibility of the inter-
vention targeting bilirubin.
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